Soon after West Nile virus (WNV) appeared in the United States (US) in 1999, several vaccine efforts were launched, leading to a vaccine deemed suitable for horses by 2001, according to Thomas Monath of Harvard Medical School in Boston, Mass. By last year, however, nearly all other WNV vaccine development efforts had stopped, leaving human populations fully vulnerable to this mosquitotransmitted disease, he says. The practical abandonment of vaccine efforts is but one peculiarity during the brief history of vector-borne WNV disease in North America. It was the focus for several discussions last September during a workshop, "Vector-Borne Diseases: Exploring the Environmental, Ecological, and Health Connections," convened by the Forum on Microbial Threats, which operates under the auspices of the Institute of Medicine (IOM) in Washington, D.C.
The obstacles to developing a WNV vaccine for humans "are not technical," Monath says. Instead, they are mainly matters of economics along with regulatory idiosyncrasies. For example, although the elderly are particularly vulnerable to WNV, it is diffıcult to say who within this population group would take a vaccine, if one were available, in large part because outbreaks tend to be regional but do not follow regular patterns from year to year. Another challenge is that Food and Drug Administration (FDA) offıcials indicated that they would require effıcacy data from a human vaccine trial to approve a WNV vaccine and would not rely on the FDA Animal Rule, a provision that accepts effıcacy data from animal studies along with safety data from testing in humans. The irregular nature of WNV outbreaks would greatly complicate planning any clinical effıcacy trials, he points out.
WNV infected as many as 5.2 million individuals in the US since 1999, but only about 1.2 million were made ill from those infections, says Lyle Petersen of the Centers for Disease Control and Prevention (CDC) in Atlanta, Ga. Although it now causes infections throughout the country, its geographic incidence pattern is highly irregular. In recent years, he notes, "South Dakota has had the highest incidence, which is odd for a 'tropical' virus." The incidence is also high in densely populated states such as California and cities such as Chicago and Phoenix.
Another peculiarity is that the three biggest outbreaks of neuroinvasive WNV, the most serious form of such infections, occurred "during heat waves" in 2002, 2006, and 2012, Petersen adds. Whether weather affects such incidence patterns is under debate, however. "Our data don't support the idea that heat waves are responsible for WNV outbreaks," says Marm Kilpatrick of the University of California, Santa Cruz. "In Texas, for example, the severity of winters appears to be more important." If human behaviors change in response to local fluctuations in weather, he adds, "predictions go out the window."
Centers for Disease Control and Prevention map of 2014 West Nile Virus activity in the United
States; human infections were reported in all but four states, and in only one state was three no human or nonhuman infections reported.
In any case, climate is but one of several factors that appear to be driving WNV incidence while the virus infects different species of birds, adapting to different hosts as they develop immunity to it, Kilpatrick says. A larger "uncertainty" resides in potential evolutionary changes in this pathogen, which is considered a relatively stable virus, as well as in its vectors and hosts.
On top of such uncertainties is unevenness in the surveillance system for following such trends, says William Karesh of the EcoHealth Alliance in New York, N.Y. "I'm not comfortable about understanding the pattern when we're investing so much less in surveillance. We need to get our surveillance system to be steady, not a roller-coaster." Moreover, amid the steady emergence of still other insect vector-borne diseases, some of the expertise needed to understand them, particularly in disciplines such as ecology and entomology, is dwindling as are the resources to train such experts, according to Petersen of CDC. Losing this capacity is "a major problem," he says.
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Post-Joint Replacement Infections Are Antibiotic-Defying, Biofilm-Like, Large Aggregates
Despite standard antibiotic prophylaxis, breakthrough infections still occur, with often devastating effects, following total joint arthroplasty. Now Noreen Hickok of the Thomas Jefferson University, Philadelphia, Pa., Michael Otto of the National Institute of Allergy and Infectious Disease, Bethesda, Md., et al. show that despite cefazolin at 100 -200 times the required concentration, Staphylococcus aureus-including MRSA-survive in synovial fluid. "When we looked at the synovial fluid containing the bacteria under the microscope, we could see large aggregates of bacteria, large enough in some cases to see with the naked eye," says Hickok. These aggregates, which are like floating biofılms, "are insensitive to antibiotics," she says. The resulting infections are very hard to treat, and in the case of implants, can result in the need for additional surgeries. "Unlike classic biofılms, these aggregates appear to have protein which may be cross-linked to form a very dense cluster of bacteria," says Hickok. "It will be a challenge both
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Various Ways Infectious Agents Are Affecting Wildlife-or Not
Recent developments in which infectious agents affect wildlife in curious ways include:
• Although dogs were likely the original source of the canine distemper virus that causes recurrent outbreaks in Serengeti lions, other members of the carnivore community appear to maintain this virus in that ecosystem, according to Mafalda Viana at the University of Glasgow in Glasgow, United Kingdom, and her collaborators. 
